Determinants of remission of paget's disease of bone
Open Access
- 1 December 1993
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of Bone and Mineral Research
- Vol. 8 (12), 1467-1473
- https://doi.org/10.1002/jbmr.5650081209
Abstract
Bisphosphonates are a safe and effective treatment for Paget's disease of bone, but little information is available about the factors influencing the duration of remission so obtained. We assessed 60 patients with Paget's disease treated with disodium pamidronate (APD). The mean duration of remission was 9.5 months (range 3–25). The major influences were the initial pretreatment alkaline phosphatase (ALP; r = −4.6, p < 0.0001), minimum posttreatment ALP (r = −0.51, p < 0.0001), and the rate of response of bone turnover to the first dose of APD (r = 0.61, p < 0.0001). Multiple linear regression showed that the initial response to treatment was the most significant influence. Also, despite a minimum ALP within the normal range, the duration of remission varied considerably (4–25 months). This may be due to the difficulties in applying a population‐based normal range to individuals.Keywords
This publication has 33 references indexed in Scilit:
- PamidronateDrugs, 1991
- Advances in the Management of Paget??s Disease of BoneDrugs, 1990
- Treatment of Paget's disease of bone with (4-chloro-phenyl) thiomethylene bisphosphonateClinical Rheumatology, 1989
- Relapse of osteoporosis circumscripta as a lytic ring after treatment of Paget's disease with intravenous 3-amino-1 hydroxypropylidene-1,1-bisphosphonateThe British Journal of Radiology, 1988
- Biological and clinical assessment of a new bisphosphonate, (chloro-4 phenyl)thiomethylene bisphosphonate, in the treatment of Paget's disease of boneBone, 1988
- Intravenous aminopropylidene bisphosphonate (APD) in the treatment of paget's bone diseaseJournal of Bone and Mineral Research, 1987
- Efficacious Management with Aminobisphosphonate (APD) in Paget??s Disease of BonePublished by Wolters Kluwer Health ,1987
- Low dose intravenous 3-amino-1-hydroxypropylidene-1,1-bisphosphonate (APD) for the treatment of Paget's disease of bone.Annals Of The Rheumatic Diseases, 1986
- EFFECTIVE ORAL TREATMENT OF SEVERE PAGET'S DISEASE OF BONE WITH APD (3‐AMINO‐I‐HYDROXYPROPYLIDENE‐1,1‐BISPHOSPHONATE); A COMPARISON WITH COMBINED CALCITONIN + EHDP (1 ‐HYDROXYETHYLIDENE‐1,1 ‐BISPHOSPHONATE)Australian and New Zealand Journal of Medicine, 1984
- Treatment of Paget's Disease of Bone with Ethane-1, Hydroxy-1,1 Diphosphonate (EHDP) at a Low Dosage (5 mg/kg/day)Published by Wolters Kluwer Health ,1983